CD8A and neoplasm: Intra-tumoral administration of LTX-315 stimulates the generation of systemic tumor-specific immune responses (10, 11), resulting in increased infiltration of cytotoxic CD8+ T cells and decreased regulatory T (Treg) cell infiltration in primary treated tumors (11–14) and in re-challenged secondary tumors (10).